Astellas Pharma Inc.’s late-stage gamble on the success of Aquinox Pharmaceuticals Inc.’s lead drug candidate in its pivotal clinical trial and initial planned indication looks set to cost the Japanese major $25m with considerably reduced prospects of any commercial pay off down the road, given rosiptor’s “definitive” failure in Phase III.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?